A Note from the Editor:


Before you discard this e-mail as Junk, you should read the next few paragraphs about our impressive rate of return on the featured companies. If you would have been fortunate enough to receive our featured companies at the time we featured them, you would have taken a $ 1000 investment to $8,860 in a span of 12 months (An increase of over 786%).  How? Easy.  Buy when we feature a company, sell when it peaks (usually within first sixty days or less) and invest all or part of it into our next feature.

Here is an example of what has happened in last few months:

  1. XMSR, feature price about $4.00 in April 2001 peaked at around $17 and stayed between $12 to $15 until middle of August.
  2. TBXR, feature price of about $1 in June 2001 peaked at around $ 2.80 and stayed above $ 2 until middle of July.

These are some of the companies. Our subscribers buy at our feature time and sell at their discretion a while later at much higher prices.

We all know that leaving our money in the bank only returns a small 3% to 5% annually. With using our featured companies, buying the stock at the right time and selling them when it has moved up, you can lock up the profits. 

If you are interested in receiving more of our features, click to the sign up section below and we will add you to our OPT-IN list. Meanwhile here is our next feature. Happy investing. Remember investing is risky and we are not investment advisors(disclaimer).You can sign up by e-mailing me at mac12344b@yahoo.com.

NOW OUR FEATURE PRESENTATION

This feature represents a tremendous investment opportunity. Our featured company is a very compelling investment choice. With its current price this company is extremely undervalued and based on EPS projections a price target could be reached in the near future.

INVESTORS SEEK SHELTER IN BIOTECHS

Samaritan Pharmaceuticals(OTCBB:SPHC)

REASONS TO BUY

1.

SPHC hits milestone completion of phase Iib Clinical Trial for ANTICORT in Patients With HIV Infection. This drug could be the First Low Cost Drug for AIDS. This study was conducted under an IND filed with the US FDA. (Aug 17 /PRNewswire)

2.

SPHC recently licensed a Early Detection Breast Cancer Patent which Identifies Protein (PBR) Responsible for Part of Cellular Changes in the Development and Progression Of Breast Cancer.

3.

SPHC recently entered into a  Seven year exclusive partnership agreements with Georgetown University..

4.

SPHC recently entered into a exclusive license with Georgetown for a patent concerning the early detection of Alzheimer˙FFFF92s and other neurodegenerative diseases by detecting increases in oxidative stress in the brain

5.

SPHC announced on September 6, that it was granted an exclusive worldwide licensing agreement to commercialize a ˙FFFF93Cholesterol Recognition Amino Acid Sequence˙FFFF94 Patented Invention for Georgetown University.


AMAZING REVENUES:

SPHC's  drug Anticort completed late stage FDA Phase Ib/IIa clinical human trials for HIV at the LA Aids Research Alliance and plans to submit final "study report" to FDA early 2002.

SPHC and Georgetown University signed a seven-year research collaboration to discover, develop, and commercialize novel therapies for Alzheimer's and Cancer.

SPHC expanded its drug portfolio beyond Anticort and has identified drug candidates for Alzheimer's and other neurodegenerative disorders, now in pre-clinical trials.
SYMBOL:

SPHC

Current Price:

.16

52 WEEK HIGH/LOW:

 $ 1.03- .11

FLOAT (est.)

  10,700,000

SHARES OUTSTANDING

  26,000,000

12 MONTH PRICE PROJ.:

$4.00

                             Quote - News
Most Recent Developments:
1.

11/16/2001 04:59 am Samaritan To Collaborate With the French Government to Develop New Drugs and Diagnostic Tools by Using Relevant Resources Available in Fran

2.

  11/15/2001 02:40 pm 10QSB: SAMARITAN PHARMACEUTICALS INC

3.

 11/6/2001 05:31 am SAMARITAN PHARMACEUTICALS INC - Samaritan Victorious -- Awarded Summary Judgment Wins $100,000 Cash - Bond Posted by Alfred T. Sapse .

About Samaritan Pharmaceuticals:

SPHC is a biopharmaceutical company focused on the commercialization of ˙FFFF93˙FFFF94drug candidates and ˙FFFF93diagnostics˙FFFF94 to combat Alzheimer, Cancer and HIV.  Samaritan˙FFFF92s drug candidate, Anticort completed FDA Phase 1b/2a Clinical human trials for HIV and company plans to submit its final Phase ll ˙FFFF93study report˙FFFF94 to the FDA early 2002.  SPHC has established research collaboration with Georgetown University giving it a research arm to develop new drug candidates and diagnostics.  The Company has an existing portfolio of three licensed ˙FFFF93drug candidates˙FFFF94. One of the drugs in the late stage FDA clinical trials and three ˙FFFF93drug candidates˙FFFF94  are in the pre-clinical stages, including an Alzheimer and Breast Cancer Diagnostic drug.  SPHC has a financial partner in Fusion Capital who has provided SPHC with an equity line of 20 million dollars which gives the Company cash, and more importantly, enough money to fund its Clinical trials.

CONCLUSION:

The Key to successful investing is finding value in something today that will be recognized by the investment community in the future. SPHC is one of those investments. For the last several years it has been developing it's products and they are very close to going to market with these drugs Projected Income to SPHC upon drug approval is expected to exceed$43 Million  in the first year and is expected to reach $ 85 Million in the third Year. We beleive SPHC has a very major upside in the near term. 
:
Disclaimer:

Certain statements contained in this news release may be forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may be identified by such terms as "expect", "believe", "may", "will", and "intend" or similar terms. We are NOT a registered investment advisor or a broker dealer This is NOT an offer to buy or sell securities. No recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learns of the profiled companies. This is an independent electronic publication that was paid $5,000 in cash by a third party for the electronic dissemination of this company information. Be advised that investments in companies profiled are considered to be high-risk and use of the information provided is for reading purposes only. If anyone decides to act as an investor they are advised not to invest without the proper advisement from an attorney or a registered financial broker, if any party decides to participate as an investor then it will be that investor's sole risk. Be advised that the purchase of such high-risk securities may result in the loss of some or all of the investment. The companies that are profiled provide all information and make no representations. The profiled companies make no warranties or guarantees as to the accuracy or the completeness of the disclosure. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. The receipt of this information shall not create, under any circumstances, any implication that there has been no change in the affairs of the company profiled since the date of review. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. All information provided by the profiled companies may include information provided by outside sources, such as research reports, public filings or computer databases and information obtained from public information available on the company.


To unsubscribe from this mailing, CLICK HERE to be removed.